combretastatin has been researched along with Disease Exacerbation in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Elming, PB; Horsman, MR; Nielsen, PS; Wittenborn, TR | 1 |
| Sherbet, GV | 1 |
1 review(s) available for combretastatin and Disease Exacerbation
| Article | Year |
|---|---|
Suppression of angiogenesis and tumour progression by combretastatin and derivatives.
Topics: Angiogenesis Inhibitors; Animals; Bibenzyls; Cell Movement; Cell Proliferation; Disease Progression; Epithelial-Mesenchymal Transition; Humans; Neoplasm Invasiveness; Neoplasms; Neovascularization, Pathologic; Signal Transduction; Tumor Burden | 2017 |
1 other study(ies) available for combretastatin and Disease Exacerbation
| Article | Year |
|---|---|
Tumors Resistant to Checkpoint Inhibitors Can Become Sensitive after Treatment with Vascular Disrupting Agents.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Bibenzyls; CTLA-4 Antigen; Diphosphates; Disease Progression; Drug Resistance, Neoplasm; Female; Immune Checkpoint Inhibitors; Male; Mammary Neoplasms, Animal; Mice; Mice, Inbred C3H; Neovascularization, Pathologic; Stilbenes; Treatment Outcome | 2020 |